Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Uges

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
British Journal of Cancer|June 1, 1995
Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancerJ A Gietema, G J Veldhuis, H J Guchelaar, et al.
British Journal of Cancer|March 10, 1999
Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecinR S de Jong, N H Mulder, D R Uges, et al.
Cancer Treatment Reports|February 1, 1987
Phase I and pharmacokinetic study of trans-N3P3Az2(NHMe)4N H Mulder, W H Meijers, J D van der Meulen, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumoursA M Bos, E G de Vries, P Dombernovsky, et al.
British Journal of Cancer|August 17, 2000
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumoursR Paridaens, D R Uges, N Barbet, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
British Journal of Cancer|June 1, 1995
Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancerJ A Gietema, G J Veldhuis, H J Guchelaar, et al.
British Journal of Cancer|March 10, 1999
Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecinR S de Jong, N H Mulder, D R Uges, et al.
Cancer Treatment Reports|February 1, 1987
Phase I and pharmacokinetic study of trans-N3P3Az2(NHMe)4N H Mulder, W H Meijers, J D van der Meulen, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumoursA M Bos, E G de Vries, P Dombernovsky, et al.
British Journal of Cancer|August 17, 2000
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumoursR Paridaens, D R Uges, N Barbet, et al.
Pageof 9